Hypolipemic Treatment in Acute Coronary Syndrome (ACS): Antithrombotic Effects
Status:
Unknown status
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The aim of the current study is to evaluate whether treatment with high doses of simvastatin
can reduce coagulation activation in patients with acute coronary syndromes and if ezetimibe
in conjunction with simvastatin may affect blood clotting in a similar manner.
The investigators hypotheses are as follows:
1. Intensive lipid lowering treatment with simvastatin (40 mg/day) and simvastatin (40
mg/day) combined with ezetimibe (10 mg/day) initiated after acute coronary syndrome
leads to attenuation of blood coagulation including reduced thrombin generation,
thrombin-mediated coagulant reactions, and improved structure of plasma clots.
2. Anticoagulant effects of simvastatin are weaker than those observed during
administration of simvastatin and ezetimibe.